Quality & complianceOfficial

FDA lists Class II recall of Victory Medical Center Pharmacy's compounded cagrilintide/glycine/B12 vials

🇺🇸 FDA enforcement report · Wed 11 Nov 2026

The recall of a 1 mL multi-dose vial product, cited for lack of processing controls, is ongoing and covers distribution in Colorado, Florida and Texas.

The US Food and Drug Administration has published a Class II recall in its enforcement report for a compounded injectable from Victory Medical Center Pharmacy. The product is listed as cagrilintide/glycine/B12 in a multi-dose vial (MDV) at 3.75/5/1 mg/mL, in a 1 mL presentation.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA enforcement report ↗

Article written by VigiEye from the official source (FDA enforcement report). AI-assisted; check the source before acting.